clinical 2,483 words KG: ent-clin-3eeade26
Contents

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study t... (NCT05348785)

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

Wikipedia

Related Hypotheses (30)

Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.48
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.79
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Senescent Cell Mitochondrial DNA Release
Score: 0.74
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Orexin-Microglia Modulation Therapy
Score: 0.71
Lysosomal Enzyme Trafficking Correction
Score: 0.71
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Lysosomal Positioning Dynamics Modulation
Score: 0.69
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.67
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
pg 1/2Next →

Related Analyses (6)

Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed

Related Experiments (3)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · completed · Score: 0.40

See Also (15)

A 6-month & 18-month Prospective, Randomized, Placebo-c
clinical · Pages share 4 hypotheses
Section 253: Advanced Optogenetics and Chemogenetics fo
therapeutic · Pages share 4 hypotheses
A Phase III, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 4 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 4 hypotheses
Mitochondrial Replacement Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.